
Cancer Epidemiology Biomarkers & Prevention Vol. 9, 221-223, February 2000
© 2000 American Association for Cancer Research
Duration of Gestation and Prostate Cancer Risk in Offspring1
Anders Ekbom,
Joanne Wuu,
Hans-Olov Adami,
Chih-Ming Lu,
Pagona Lagiou,
Dimitrios Trichopoulos and
Chung-cheng Hsieh2
Department of Medical Epidemiology, Karolinska Institute, Stockholm S-171 77, Sweden [A. E., H-O. A.]; University of Massachusetts Cancer Center, Worcester, Massachusetts 01605 [J. W., C-M. L., C-c. H.]; Department of Urology, Tian-Sheng Memorial Hospital, Pingtung 928, Taiwan [C-M. L.]; Department of Epidemiology, Harvard School of Public Health and Harvard Center for Cancer Prevention, Boston, Massachusetts 02115 [D. T., C-c. H.]; and University of Athens, Athens 115 27, Greece [P. L., D. T.]
 |
Abstract
|
|---|
This large population-based nested case-control study investigated the
importance of perinatal characteristics as risk factors for prostate
cancer in later life in a cohort of men who were born between 1889 and
1941 in Stockholm, Sweden. Eight hundred and thirty-four prostate
cancer cases over 18 years of age and of singleton birth were
identified from the cohort between 1958 and 1994. For each case,
singleton males born live to the first four mothers admitted after the
cases mother were selected as potential controls; 1880 eligible
controls were included in the study. For each study subject, we
obtained data on mothers parity, pre-eclampsia or eclampsia before
delivery, age at delivery, and socioeconomic status, as well as
childs birth length and weight, placental weight, and gestational
age. Odds ratio (OR) estimates and 95% confidence intervals (CIs) were
derived from logistic regression analyses. We found no statistically
significant differences between cases and controls with respect to
maternal age, socioeconomic status, or parity. Birth weight, birth
length, and placental weight were also not significantly related to
prostate cancer risk. Pregnancy toxemia (OR = 0.33; 95% CI,
0.071.45) and longer gestation age were associated with a reduced
risk of prostate cancer; the OR estimate was 0.94 (95% CI, 0.890.99)
for each 1-week prolongation of the duration of gestation. Our results
suggest that birth size indicators are not important risk factors for
prostate cancer in later life. In addition, our data on gestation age
indicate that the late in utero environment may be as
important as the early in utero environment in the
modulation of prostate cancer risk in offspring.
 |
Introduction
|
|---|
The hypothesis that intrauterine hormones may affect prostate
cancer risk in offspring was advanced by Henderson et al.
(1)
and Ross and Henderson (2)
, who focused
on the early in utero estrogen and testosterone environment
that could affect the hypothalamic-pituitary-testicular feedback system
through imprinting. Evidence for perinatal influences on prostate
cancer risk was revealed in a small cohort study in Gothenberg, Sweden,
where a strong positive association between birth weight and prostate
cancer risk was reported (3)
. Fetal growth and
pre-eclampsia or eclampsia are correlated with concentrations of
pregnancy hormones (4)
. In a nested case-control study in
Uppsala, Sweden, nonsignificant positive associations of prostate
cancer risk with several birth size indicators and a significant
inverse association with pregnancy toxemia were reported
(4)
. Furthermore, a retrospective analysis of birth weight
in relation to prostate cancer found no overall association between
birth weight and prostate cancer incidence and found weak and
nonsignificant evidence for a positive association between birth weight
and high-stage/grade prostate cancer (5)
. To assess the
importance of perinatal characteristics as risk factors for prostate
cancer in later life, we performed a large population-based nested
case-control study in Stockholm, Sweden.
 |
Subjects and Methods
|
|---|
Because there is no private inpatient treatment in Sweden,
hospital services are population based. We have attempted to identify
all men born between 1889 and 1941 at the two major delivery centers in
Stockholm who were residents of the city of Stockholm on or after
January 1, 1947 and were alive in 1958. The individually unique
national registration number used for identification and follow-up was
introduced for all Swedish residents in 1947. The first six digits
provide the date of birth (year, month, and day), whereas the seventh
and eighth digits provide information on county of birth or residency
on January 1, 1947.
In Sweden, all patients newly diagnosed with malignant tumors must be
reported by both the diagnosing physician and the pathologist or
cytologist to one of six regional cancer registries, which pass data to
the national cancer registry established in 1958. At the time of this
study, the national cancer registry was complete through December 31,
1994.
All men in the national cancer registry with a diagnosis of prostate
cancer (International Classification of Diseases 7, code 177)
and a city code for Stockholm in their national registration number
were included in the study. Cases may have been missed if a man born at
one of the two delivery centers moved out of the city before 1947 and
subsequently developed prostate cancer. From the county in which each
patient lived when prostate cancer was diagnosed, we were able to
establish his place of birth and family name at birth. At this stage,
patients not born at one of the two delivery centers were excluded.
Fatal cases, whose underlying cause of death on the death certificate
was stated to be prostate cancer, were identified by linkage with the
Death Registry.
Eight hundred and thirty-four prostate cancer cases over age 18 years
and of singleton birth were identified. For each case, singleton males
born live to the first four mothers admitted after the cases mother
were selected as potential controls. We used the cancer and death
registries to check that potential control subjects were alive and had
not had prostate cancer diagnosed at the time of diagnosis of the
corresponding case; 1880 eligible controls were included in the study.
For all cases and their matched controls, we manually abstracted
information on mothers parity, pre-eclampsia or eclampsia before
delivery, age at delivery, and socioeconomic status from the
standardized hospital chart. We also recorded the childs birth length
and weight, placental weight, and gestational age in completed weeks
calculated from the first day of last menstruation. The completeness of
records exceeded 95% for every item in the study, with the exception
of placental weight, which was only recorded at one of the two delivery
centers.
We analyzed the data using logistic regression conditional on the
matching process (6)
. Different sets of models were fitted
to assess the effect of birth size indicators including birth weight,
birth length, and placental weight. Each of the birth size indicators
was introduced alternatively into a core model to avoid problems of
collinearity. The core model included maternal age (<20, 2024,
2529, 3034,
35 years; as a categorical variable), socioeconomic
status (low, medium, high; as an ordinal variable), parity (1, 23,
4; as a categorical variable), pregnancy toxemia (pre-eclampsia or
eclampsia; yes or no), and gestation age (in weeks; as a continuous
variable).
OR3
estimates and 95% CIs were derived from the fitted regression
(7)
. The level of significance was set at
P < 0.05 (two-sided P).
 |
Results
|
|---|
Of 834 cases, 1.8% were born before 1900, 55.6% were born
between 1900 and 1919, and 42.6% were born in 1920 or later. The
corresponding numbers among the 1880 control subjects were 1.1%,
47.6%, and 51.3%, respectively. Maternal age had an inverse U-shaped
relation with prostate cancer risk; subjects born to younger (<25
years) and older mothers (
35 years) were at lowered risk (Table 1)
. We found no statistically significant differences between cases and
controls with respect to socioeconomic status. High birth order, as
indicated by high maternal parity, was associated with an increased
risk. A recorded pre-eclampsia or eclampsia appeared to be associated
with a reduced risk for prostate cancer, but the risk estimate was
based on a few exposed subjects and was hence statistically imprecise.
Birth weight, birth length, and placental weight, adjusted one at a
time for gestational age, were also not significantly related to
prostate cancer risk. The effect estimates for birth size indicators
varied over different strata of gestation age: near null associations
were seen in the strata of 3741 and
42 weeks of gestation, and
positive associations were seen in preterm (<37 weeks) stratum.
However, with a smaller number of preterm subjects (7.4% of cases and
6.1% of controls), stratum-specific OR estimates had CIs that were
wide and included null value (data not shown). Gestational age,
however, tended to be inversely associated with risk for prostate
cancer: OR associated with each additional week of gestation was 0.97
(95% CI, 0.941.01); and it was 1.31 (95% CI, 0.931.84)
comparing preterm (<37 weeks) to full-term (
37 weeks) subjects. The
inverse association was not changed after adjustment for the
alternative birth size indicators to remove potential confounding
(Table 1)
. Indeed, when placental weight, rather than birth weight or
length, was adjusted for, the inverse association of gestational age
with prostate cancer risk became statistically significant, indicating
that prolongation of the duration of gestation by 1 week is associated
with a 6% reduction in prostate cancer risk (Table 1)
. Preterm
subjects had an OR of 1.76 (95% CI, 1.152.71) as compared to
full-term subjects in the analysis adjusting for placental weight. To
potentially separate the effects of intrauterine growth retardation
from prematurity, we examined the effect associated with
small-for-gestational-age subjects, defined as those below the
10th percentile of birth weight for a given gestational age
according to Swedish population distribution (8)
,
and found an insignificant OR of 1.05 (95% CI, 0.761.47)
compared to normal-for-gestational-age subjects. Risk estimates similar
to those found in the main analysis on birth size variables and
gestational age were obtained when subjects were stratified by age
(<70 years,
70 years), as well as when the alternative outcome of
fatal cases was examined.
View this table:
[in this window]
[in a new window]
|
Table 1 Conditional logistic regression-derived ORs (and 95% CIs) for prostate
cancer in relation to a series of maternal and perinatal
characteristics
|
|
 |
Discussion
|
|---|
Selection and information biases are unlikely in our nested
case-control study because this design preserved the validity of a
cohort study. However, data on maternal diabetes were not available.
During the period when the study subjects were born, most diabetic
women were unlikely to complete the pregnancies, and very few subjects
would be born to diabetic mothers. On the other hand, having
information on perinatal characteristics available from birth records
is a major strength of this study.
For most exposures, the study was sufficiently large to document risk
gradients of even moderate size. Taken together with the results of the
two previous large studies (4
, 5)
, our results suggest
that birth size indicators are not important risk factors for prostate
cancer in later life. Our findings do not refute a possible inverse
association between pregnancy toxemia and prostate cancer risk and
agree with those in a previous study. If results from the two studies
we have thus far conducted are pooled to gain statistical power, the
combined OR is 0.16 (95%CI, 0.030.72; P = 0.01), but
evidence from other populations is clearly needed to establish (or
refute) this association.
The novel result of the present study was the inverse association
between gestational age and prostate cancer risk after adjustment for
birth size indicators and, in particular, placental weight. Placental
weight is an important correlate of pregnancy hormone levels, and its
adjustment is likely to better unmask the effect of gestation age
(4
, 9) . Although chance cannot be ruled out as a possible
explanation for this finding, and maternal levels of other hormones
also change with gestational age, to the extent that pregnancy estrogen
increases exponentially with gestational age, pregnancy estrogens are
higher in women with low parity, and estrogen plays an inhibitory role
in the natural history of prostate cancer, this finding appears to
support the hypothesis that the intrauterine hormonal environment
modulates prostate cancer risk (1
, 2)
. However, our data
suggest that the late in utero environment may be as
important as the early in utero environment in the
modulation of prostate cancer risk in offspring.
 |
Acknowledgments
|
|---|
We thank Ulrika Lund and Ann Almqvist for the retrieval process
and anonymous reviewers for helpful comments.
 |
Footnotes
|
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 Supported by American Cancer Society Grant
EDT-120. 
2 To whom requests for reprints should be
addressed, at University of Massachusetts Cancer Center, 373 Plantation
Street, Suite 211, Worcester, MA 01605. Phone: (508) 856-4780; Fax:
(508) 856-2212; E-mail: chung.hsieh{at}umassmed.edu 
3 The abbreviations used are: OR, odds ratio; CI,
confidence interval. 
Received 7/13/99;
revised 10/15/99;
accepted 11/15/99.
 |
References
|
|---|
-
Henderson B. E., Bernstein L., Ross R. K., Depue R. H., Judd H. L. The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. Br. J. Cancer, 57: 216-218, 1988.[Medline]
-
Ross R. K., Henderson B. E. Do diet and androgens alter prostate cancer risk via a common etiologic pathway?. J. Natl. Cancer Inst., 86: 252-254, 1994.[Free Full Text]
-
Tibblin G., Eriksson M., Cnattingius S., Ekbom A. High birth weight as a predictor of prostate cancer risk. Epidemiology, 6: 423-424, 1995.[Medline]
-
Ekbom A., Hsieh C-c., Lipworth L., Wolk A., Ponten J., Adami H-O., Trichopoulos D. Perinatal characteristics in relation to incidence of and mortality from prostate cancer. Br. Med. J., 313: 337-341, 1996.[Abstract/Free Full Text]
-
Platz E. A., Giovannucci E., Rimm E. B., Curhan G. C., Spiegelman D., Colditz G. A., Willett W. C. Retrospective analysis of birth weight and prostate cancer in the Health Professionals Follow-up Study. Am. J. Epidemiol., 147: 1140-1144, 1998.[Abstract/Free Full Text]
-
Breslow N. E., Day N. E. Statistical Methods in Cancer Research. The Analysis of Case-Control Studies, Vol. I: IARC Lyon, France 1980.
-
Statistical Analysis Systems . SAS Users Guide, Statistics, version 6.04, SAS Institute Inc. Cary, NC 1995.
-
Cnattingius S., Haglund B., Kramer M. S. Differences in late fetal death rates in association with determinants of small for gestational age fetuses: population-based cohort study. Br. Med. J., 316: 1483-1487, 1998.[Abstract/Free Full Text]
-
Ekbom A., Trichopoulos D., Adami H-O., Hsieh C-c., Lan S-J. Evidence of prenatal influences on breast cancer risk. Lancet, 340: 1015-1018, 1992.[Medline]